Taysha Gene Therapies, INC

Taysha Gene Therapies has priced an underwritten public offering of common stock and pre-funded warrants to raise approximately $200 million in gross proceeds.

Taysha Gene Therapies reported Q1 2026 results, highlighting FDA alignment on the TSHA-102 Biologics License Application pathway and continued clinical trial progress for Rett syndrome.

Taysha Gene Therapies reported full-year 2025 financial results and provided a corporate update, highlighting significant progress in its TSHA-102 Rett syndrome program and a strong cash position.

Taysha Gene Therapies announced FDA Breakthrough Therapy designation for TSHA-102, finalized pivotal trial protocol, and increased its ATM offering to $212 million, alongside Q3 2025 financial results.

Taysha Gene Therapies has regained full global rights to its lead TSHA-102 program for Rett syndrome after its option agreement with Astellas expired.

Taysha Gene Therapies announced new supplemental data from its REVEAL Phase 1/2 trials for TSHA-102 in Rett Syndrome, showing 100% of patients achieved multiple functional gains.

Taysha Gene Therapies reports increased R&D spending and net loss in Q1 2026, with cash reserves projected to fund operations into 2028.

Taysha Gene Therapies reports significant clinical progress for TSHA-102 in Rett syndrome, securing Breakthrough Therapy designation and extending its cash runway into 2028 through a new term loan and equity offering.

Taysha Gene Therapies reports positive clinical data for TSHA-102 in Rett syndrome and secures significant financing, extending cash runway into 2028.

Taysha Gene Therapies reports a net loss for Q1 2025 while advancing its TSHA-102 clinical program for Rett syndrome.

Taysha Gene Therapies reports a net loss of $25.5 million for Q3 2024, while highlighting progress in its TSHA-102 clinical trials for Rett syndrome.

Taysha Gene Therapies reported its Q2 2024 financial results, highlighting progress in its Rett syndrome clinical trials and ongoing financial strategies.

Taysha Gene Therapies reports positive clinical data for TSHA-102 in Rett syndrome, progresses pivotal trials, and extends its cash runway into 2028 through recent capital raises.

Taysha Gene Therapies' 2024 10-K filing details the company's financial performance and clinical advancements, particularly in its TSHA-102 program for Rett syndrome.

Taysha Gene Therapies' annual 10-K filing highlights its focus on Rett syndrome treatment with TSHA-102, while discontinuing the TSHA-120 program for GAN and seeking strategic options for other pipeline assets.

Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, Inc., reported a sale of 200,000 shares under a Rule 10b5-1 trading plan.

John A. Stalfort III, a Director at Taysha Gene Therapies, Inc., acquired restricted stock units and stock options.

Phillip B. Donenberg, a Director at Taysha Gene Therapies, Inc., acquired restricted stock units and stock options on June 1, 2026.

Director Alison S. Long acquired 21,335 shares of common stock and 42,671 stock options in Taysha Gene Therapies, Inc. (TSHA) on June 1, 2026.

Director Laura Sepp-Lorenzino acquired restricted stock units and stock options in Taysha Gene Therapies, Inc. (TSHA) on June 1, 2026.

Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, reports transactions involving common stock and employee stock options.

Taysha Gene Therapies, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 1, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.

Taysha Gene Therapies files an amendment to its proxy statement solely to include Inline eXtensible Business Reporting Language (XBRL) data tagging, which was initially omitted.

Taysha Gene Therapies is holding its 2025 Annual Meeting on June 2, 2025, seeking stockholder votes on director elections, auditor ratification, and an increase in authorized common stock.

Taysha Gene Therapies is holding its annual stockholder meeting on June 2, 2025, to vote on director elections, auditor ratification, and an increase in authorized common stock.

Taysha Gene Therapies announces its 2024 Annual Meeting of Stockholders, urging shareholders to vote on key proposals including the election of directors and ratification of the company's independent auditor.

Taysha Gene Therapies announces its Annual Meeting of Stockholders to be held virtually on May 29, 2024, featuring proposals for director elections and ratification of the company's independent accounting firm.

Paul B. Manning and a group of affiliated entities have increased their beneficial ownership in Taysha Gene Therapies, Inc. to 9.8% of the outstanding common stock through recent purchases in public offerings.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 6.3% beneficial ownership stake in Taysha Gene Therapies, Inc.

RTW Investments, LP and Roderick Wong have reported a significant beneficial ownership stake of 7.0% in Taysha Gene Therapies, Inc., holding over 20.6 million shares.

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 8.3% in Taysha Gene Therapies, Inc., including warrants.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 4.9% in Taysha Gene Therapies Inc., marking a reduction below the 5% threshold.

BlackRock, Inc. has reported a 6.5% beneficial ownership stake in Taysha Gene Therapies Inc. common stock as of December 31, 2025.

Octagon Capital Advisors LP and its affiliates have reported a 3.3% beneficial ownership stake in Taysha Gene Therapies, Inc., totaling 9,067,500 common shares.